Wall Street brokerages expect NextGen Healthcare, Inc. (NASDAQ:NXGN) to announce $137.30 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for NextGen Healthcare’s earnings, with estimates ranging from $135.80 million to $139.60 million. NextGen Healthcare posted sales of $137.74 million during the same quarter last year, which suggests a negative year over year growth rate of 0.3%. The business is expected to announce its next quarterly earnings results on Thursday, January 28th.
On average, analysts expect that NextGen Healthcare will report full year sales of $546.39 million for the current fiscal year, with estimates ranging from $540.20 million to $549.70 million. For the next year, analysts anticipate that the business will report sales of $566.60 million, with estimates ranging from $543.40 million to $590.40 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow NextGen Healthcare.
NextGen Healthcare (NASDAQ:NXGN) last issued its quarterly earnings results on Thursday, October 22nd. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.10. The company had revenue of $140.00 million for the quarter, compared to the consensus estimate of $133.04 million. NextGen Healthcare had a return on equity of 11.28% and a net margin of 1.80%. The firm’s revenue was up 4.3% compared to the same quarter last year. During the same period last year, the business posted $0.24 earnings per share.
A number of equities research analysts recently weighed in on the company. Morgan Stanley lifted their target price on NextGen Healthcare from $12.00 to $14.00 and gave the stock an “underweight” rating in a research report on Monday, October 26th. Colliers Securities reissued a “buy” rating on shares of NextGen Healthcare in a research report on Friday, December 11th. BidaskClub raised NextGen Healthcare from a “hold” rating to a “buy” rating in a research report on Thursday, October 8th. Cantor Fitzgerald lifted their target price on NextGen Healthcare from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Friday, October 23rd. Finally, SVB Leerink lifted their target price on NextGen Healthcare from $12.00 to $14.00 and gave the stock a “market perform” rating in a research report on Friday, October 23rd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $13.13.
In other news, Director George H. Bristol sold 4,800 shares of NextGen Healthcare stock in a transaction that occurred on Thursday, December 3rd. The shares were sold at an average price of $17.52, for a total value of $84,096.00. Following the completion of the transaction, the director now owns 67,061 shares in the company, valued at $1,174,908.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 18.70% of the company’s stock.
Several large investors have recently bought and sold shares of NXGN. Nisa Investment Advisors LLC acquired a new stake in NextGen Healthcare during the 3rd quarter worth $34,000. Advisor Group Holdings Inc. boosted its stake in NextGen Healthcare by 114.1% in the 2nd quarter. Advisor Group Holdings Inc. now owns 7,622 shares of the company’s stock worth $84,000 after purchasing an additional 4,062 shares during the period. Bank of Montreal Can lifted its position in NextGen Healthcare by 1,986.3% during the 2nd quarter. Bank of Montreal Can now owns 9,910 shares of the company’s stock worth $104,000 after buying an additional 9,435 shares in the last quarter. Meeder Asset Management Inc. lifted its position in NextGen Healthcare by 19.7% during the 3rd quarter. Meeder Asset Management Inc. now owns 10,581 shares of the company’s stock worth $135,000 after buying an additional 1,738 shares in the last quarter. Finally, Diversified Trust Co lifted its stake in NextGen Healthcare by 16.7% in the 3rd quarter. Diversified Trust Co now owns 12,427 shares of the company’s stock valued at $158,000 after purchasing an additional 1,778 shares during the last quarter. Institutional investors own 67.16% of the company’s stock.
Shares of NASDAQ:NXGN traded up $0.78 during midday trading on Friday, hitting $21.25. The company’s stock had a trading volume of 343,133 shares, compared to its average volume of 275,579. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of 133.13, a PEG ratio of 3.33 and a beta of 1.23. The stock’s 50 day simple moving average is $18.30 and its 200 day simple moving average is $14.55. NextGen Healthcare has a fifty-two week low of $5.10 and a fifty-two week high of $21.84. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.64 and a current ratio of 1.64.
About NextGen Healthcare
NextGen Healthcare, Inc provides ambulatory-focused healthcare software and services solutions in the United States. The company offers NextGen Enterprise electronic health record (EHR), which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools.
Read More: What is an overbought condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NextGen Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextGen Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.